Covered recipient · General Payments record
ANUPAMA POLIYEDATH
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2020–2024
$246.45
- Reported across 12 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $204.85 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $39.24 | 2 |
| QIAGEN, LLC | $23.39 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.75 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $22.18 | 1 |
| Abbott Laboratories | $22.05 | 1 |
| ABBVIE INC. | $20.72 | 1 |
| Lexicon Pharmaceuticals, Inc. | $19.74 | 1 |
| DEXCOM, INC. | $19.28 | 1 |
| Lilly USA, LLC | $15.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.05 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125118768 | CMS |
| ABBVIE INC. | $20.72 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105286616 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.75 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118053317 | CMS |
| Dexcom, Inc. | $19.28 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153282445 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $22.18 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153753475 | CMS |
| Lexicon Pharmaceuticals, Inc. | $19.74 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1081724759 | CMS |
| Lilly USA, LLC | $15.50 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136053614 | CMS |
| Novo Nordisk Inc | $15.53 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096955052 | CMS |
| Novo Nordisk Inc | $23.71 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096935577 | CMS |
| QIAGEN, LLC | $23.39 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153989465 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2020 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.